Aktis Oncology (NASDAQ:AKTS) Sets New 12-Month Low – Should You Sell?

Aktis Oncology (NASDAQ:AKTS) shares hit a new 52-week low on Wednesday . The company traded as low as $18.02 and last traded at $18.45, with a volume of 176838 shares trading hands. The stock had previously closed at $20.90.

Key Headlines Impacting Aktis Oncology

Here are the key news stories impacting Aktis Oncology this week:

• Positive Sentiment: Several major firms initiated coverage with bullish ratings, signaling institutional interest and meaningful upside: Bank of America started coverage with a “Buy” and a $34.00 target (implies ~72% upside from the cited price).
• Positive Sentiment: TD Cowen initiated a Buy, highlighting Aktis’s differentiated miniprotein radiopharma platform and multi‑billion dollar sales potential; this research underpins the recent positive momentum. Aktis Oncology: Differentiated Miniprotein Radiopharma Platform Underpins Buy Rating
• Positive Sentiment: Leerink Partners initiated with an “Outperform” and $31 price target (~58% upside), and coverage was picked up in media summaries. Leerink Coverage Zacks Summary
• Positive Sentiment: JPMorgan initiated coverage with an “Overweight” and a $30 target (~52% upside), adding another institutional endorsement cited in market press. JPMorgan Coverage
• Neutral Sentiment: Published short‑interest reports for early February show anomalous/zero values (0 shares, “NaN” changes and a 0.0 days ratio) — this appears to be a data error and provides no reliable signal about bearish positioning. (Two similarly worded short‑interest entries were posted 2/2 and 2/3.)
• Negative Sentiment: Despite the analyst initiations, the stock is down today — suggesting either profit‑taking after recent strength, investors awaiting clinical/data catalysts, or broader market weakness outweighing the new positive research calls.

Wall Street Analyst Weigh In

A number of analysts have commented on AKTS shares. Bank of America began coverage on Aktis Oncology in a research report on Tuesday. They issued a “buy” rating and a $34.00 price target for the company. Wall Street Zen upgraded shares of Aktis Oncology to a “hold” rating in a report on Saturday, January 17th. TD Cowen initiated coverage on Aktis Oncology in a report on Tuesday. They set a “buy” rating on the stock. JPMorgan Chase & Co. initiated coverage on Aktis Oncology in a research report on Tuesday. They issued an “overweight” rating and a $30.00 price target for the company. Finally, Leerink Partners initiated coverage on shares of Aktis Oncology in a research note on Tuesday. They issued an “outperform” rating and a $31.00 target price on the stock. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $31.67.

Aktis Oncology Trading Down 4.7%

Insider Buying and Selling

In related news, major shareholder Vida Ventures Ii, Llc acquired 835,000 shares of Aktis Oncology stock in a transaction on Monday, January 12th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $15,030,000.00. Following the completion of the transaction, the insider owned 5,671,825 shares of the company’s stock, valued at approximately $102,092,850. The trade was a 17.26% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Ecor1 Capital, Llc bought 2,222,222 shares of the firm’s stock in a transaction dated Monday, January 12th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $39,999,996.00. Following the transaction, the director owned 4,348,658 shares of the company’s stock, valued at approximately $78,275,844. This represents a 104.50% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired a total of 6,117,776 shares of company stock valued at $110,119,968 in the last three months.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.